Edgar Filing: Esperion Therapeutics, Inc. - Form 4

Esperion Thera	peutics, Inc.											
Form 4												
May 16, 2014	л							OMB A	PPROVAL			
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549									3235-0287			
Check this b if no longer subject to Section 16. Form 4 or		STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES										
Form 5 obligations may continu <i>See</i> Instruct 1(b).	e. Section 17	response 0 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type Res	ponses)											
1. Name and Address of Reporting Person <u>*</u> VITULLO NICOLE			Symbol	er Name an		-	5. Relationship of Reporting Person(s) to Issuer					
_		•	•		c. [ESPR]	(Check all applicable)						
(Last) (First) (Middle) C/O DOMAIN ASSOCIATES, LLC, ONE PALMER SQUARE			3. Date of Earliest Transaction (Month/Day/Year) 05/15/2014				XDirectorX10% Owner Officer (give titleOther (specify below) below)					
LLC, UNE PA	AKE	4 TE A	d D		1	6 Individual or Isiat/Course Ellis (Chart						
PRINCETON		4. If Amendment, Date Original Filed(Month/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person 						
(City)	(State)	(Zip)				~						
•	. ,			ole I - Non-J 3.			cquired, Disposed					
	Transaction Date Ionth/Day/Year)	Execution any	Execution Date, if		4. Securities nsactionAcquired (A) or de Disposed of (D) str. 8) (Instr. 3, 4 and 5) (A) or		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code V	Amount	(D) Price	(Instr. 3 and 4)					
Reminder: Report	on a separate line	e for each cla	ass of sec	urities bene	ficially own	ned directly of	or indirectly.					
					inforn requir	nation cont ed to respo	spond to the colle ained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)			

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number	6. Date Exercisable and	7. Title and Amount of	8. I
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	onof Derivative	Expiration Date	Underlying Securities	Der
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	Sec

number.

Edgar Filing: Esperion Therapeutics, Inc. - Form 4

(Instr. 3)	Price of Derivative Security	erivative		(Instr.	8)	(A) or Dispose (D)	Disposed of (D) (Instr. 3, 4,				
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 14.42	05/15/2014		А		5,000		<u>(1)</u>	05/15/2024	Common Stock	5,000

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
VITULLO NICOLE C/O DOMAIN ASSOCIATES, LLC ONE PALMER SQUARE PRINCETON, NJ 08542	Х	Х					
Signatures							
/s/ Kathleen K. Schoemaker, Attorney-in-Fact	05/16/2014						
<u>**</u> Signature of Reporting Person	Date						

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The option vests in full on the earlier of (i) May 15, 2015 or (ii) the Issuer's next annual meeting of stockholders following May 15, 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

(In